Insmed Surges 33% on Q2 Beat, Raises Brinsupri Guidance to $1.4B
INSM sits 45% above its 52-week low of $90.39.
Summary
Insmed shares jumped 33% after reporting Q2 revenue of $425.5M, nearly quadrupling year-over-year, and a net loss of just $13.2M, down from $321.7M. The beat was driven by Brinsupri, which generated $309.2M in its second quarter on the market, up 49% sequentially. Management raised full-year Brinsupri guidance to $1.25B-$1.40B, signaling confidence in the launch trajectory. This follows the 10-Q and 8-K filed earlier today, with the market reacting to the magnitude of the revenue acceleration and the path to profitability. The raised guidance and strong sequential growth suggest the launch is exceeding expectations, a material positive for a company approaching breakeven.
At the time of this announcement, INSM was trading at $131.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.4B. The 52-week trading range was $90.39 to $212.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.